1. | 7senza6 | |
2. | GeniusByTrade | |
3. | cspmedia | |
4. | blackopsstreet | |
5. | TradeChem |
1. | 7senza6 | |
2. | GeniusByTrade | |
3. | cspmedia | |
4. | blackopsstreet | |
5. | TradeChem |
1. | 7senza6 02/09/2018 Risk Assessment Committee (PRAC) |
2. | zhiggeOS29 10/18/2017 The Biggest Loser: Allergan's Patent Troubles |
3. | GeniusByTrade 01/10/2018 Allergan Is Set Up for Success in 2018, UBS Says |
4. | cspmedia 02/06/2018 Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute T… |
5. | barthax 08/03/2018 Spanish pharmaceutical company Almirall said it had agreed to buy five dermatology brands from U.S. company |
6. | 7senza6 02/01/2018 Allergan to pay Teva Pharm $700 million to settle dispute |
7. | TradeChem 04/30/2018 Mizuho Securities reiterates Hold rating, $185 PT |
8. | nsinaver 07/19/2018 Releases 'two positive clinical trials, SEQUOIA and CEDAR for abicipar |
9. | GeniusByTrade 02/28/2018 News out here |
10. | blackopsstreet 04/02/2018 Report of potential Womens health unit sale; could be a +$5 billion deal |